Characterization of a human antibody fragment fab and its calcium phosphate nanoparticles that inhibit rabies virus infection with vaccine

PLoS ONE

Volumn 6, Issue 5, 2011, Pages

  Liu, Xinjian ^a   Lin, Hong ^a,c   Tang, Qi ^a   Li, Chen ^a   Yang, Songtao ^d   Wang, Zhongcan ^b   Wang, Changjun ^b   He, Qing ^a   Cao, Brian ^c   Feng, Zhenqing ^a   Guan, Xiaohong ^a   Zhu, Jin ^a,b  

^a NANJING MEDICAL UNIVERSITY   (China)

^b Huadong Medical Institute of Biotechniques   (China)

^c VAN ANDEL INSTITUTE   (United States)

^d BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM PHOSPHATE; FAB094; IMMUNOGLOBULIN F(AB) FRAGMENT; NANOPARTICLE; RABIES IMMUNOGLOBULIN; RABIES VACCINE; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; ANTIGEN; IMMOBILIZED PROTEIN; PEPTIDE LIBRARY; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY LIBRARY; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; INFECTION PREVENTION; MASS SPECTROMETRY; MOLECULAR CLONING; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; RABIES; VIRION; VIRUS NEUTRALIZATION; AMINO ACID SEQUENCE; ANIMAL; CELL LINE; CHEMISTRY; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOLOGY; KAPLAN MEIER METHOD; MOLECULAR GENETICS; POLYACRYLAMIDE GEL ELECTROPHORESIS; RABIES VIRUS; SERODIAGNOSIS; VIROLOGY; WESTERN BLOTTING;

RABIES VIRUS;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, VIRAL; ANTIGENS; BLOTTING, WESTERN; CALCIUM PHOSPHATES; CELL LINE; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMOBILIZED PROTEINS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOPRECIPITATION; KAPLAN-MEIER ESTIMATE; MASS SPECTROMETRY; MICE; MOLECULAR SEQUENCE DATA; NANOPARTICLES; NEUTRALIZATION TESTS; PEPTIDE LIBRARY; RABIES; RABIES VACCINES; RABIES VIRUS;

EID: 79955911893     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0019848     Document Type: Article

References (25)

1. Ando T, Yamashiro T, Takita-Sonoda Y, Mannen K, Nishizono A, (2005) Construction of human Fab library and isolation of monoclonal Fabs with rabies virus-neutralizing ability. Microbiol Immunol 49: 311-22.
2. Meslin FX, Stohr K, (2001) Prospects for immunization against rabies in developing countries. pp. 15-18 Rabies control in Asia, John Libbey Eurotext. Montrouge.
3. World Health Organization. (2005) WHO Expert Consultation on Rabies. First Report. WHO Technical Report Series, No 931. Available from http://www.wpro.who.int/sites/csr/documents/data_rabies931.htm.
4. Wilde H, Briggs DJ, Meslin FX, Hemachudha T, Sitprija V, (2003) Rabies update for travel medicine advisors. Clin Infect Dis 37: 96-100.
5. World Health Organization. (1996) WHO recommendations on rabies post-exposure treatment and the correct technique of intradermal immunization against rabies pp. 1-24.
6. Sloan SE, Hanlon C, Weldon W, Niezgoda M, Blanton J, et al. (2007) Identification and characterization of a human monoclonal antibody that potently neutralizes a broad panel of rabies virus isolates. Vaccine 25: 2800-10.
7. Redwan el-RM, Fahmy A, El Hanafy A, Abd El-Baky N, Sallam SM, (2009) Ovine anti-rabies antibody production and evaluation. Comp Immunol Microbiol Infect Dis 32: 9-19.
8. Ray K, Embleton MJ, Jailkhani BL, Bhan MK, Kumar R, (2001) Selection of single chain variable fragments (scFv) against the glycoprotein antigen of the rabies virus from a human synthetic scFv phage display library and their fusion with the Fc region of human IgG1. Clin Exp Immunol 125: 94-101.
9. Wagner S, Rothweiler F, Anhorn MG, Sauer D, Riemann I, et al. (2010) Enhanced drug targeting by attachment of an anti alphav integrin antibody to doxorubicin loaded human serum albumin nanoparticles. Biomaterials 31: 2388-98.
10. Cho K, Wang X, Nie S, Chen ZG, Shin DM, (2008) Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res 14: 1310-6.
11. Allen TM, Cullis PR, (2004) Drug delivery systems: entering the mainstream. Science 303: 1818-22.
12. Stayton PS, Hoffman AS, Murthy N, Lackey C, Cheung C, et al. (2000) Molecular engineering of proteins and polymers for targeting and intracellular delivery of therapeutics. J Control Release 65: 203-20.
13. Ming PG, Sun W, XU GL, Wu J, Yang XM, et al. GP gene sequencing of three passages of current rabies vaccine strain CTN-1-V in China. Chin J Biologicals (in Chinese) 2006;19: 217-35.
14. Barbas CarlosF III, Burton DennisR, Scott JamieK, Silverman GreggJ, (2004) Phage display: A laboratory manual. 1rd ed New York Gold spring harbor laboratory press.
15. Houimel M, Dellagi K, (2009) Peptide mimotopes of rabies virus glycoprotein with immunogenic activity. Vaccine 27: 4648-55.
16. Bakker AB, Marissen WE, Kramer RA, Rice AB, Weldon WC, et al. (2005) Novel Human Monoclonal Antibody Combination Effectively Neutralizing Natural Rabies Virus Variants and Individual In Vitro Escape Mutants. J Virol 79: 9062-8.
17. Bourhy H, Sureau P, (1990) Laboratory methods for rabies diagnosis Paris Institut Pasteurp pp. 191-3.19.
18. Feyssaguet M, Dacheux L, Audry L, Compoint A, Morize JL, et al. (2007) Multicenter comparative study of a new ELISA, PLATELIA RABIES II, for the detection and titration of anti-rabies glycoprotein antibodies and comparison with the rapid fluorescent focus inhibition test (RFFIT) on human samples from vaccinated and non-vaccinated people. Vaccine 25: 2244-51.
19. de Kruif J, Bakker AB, Marissen WE, Kramer RA, Throsby M, et al. (2007) A human monoclonal antibody cocktail as a novel component of rabies postexposure prophylaxis. Annu Rev Med 58: 359-68.
20. Goudsmit J, Marissen WE, Weldon WC, Niezgoda M, Hanlon CA, et al. (2006) Comparison of an anti-rabies human monoclonal antibody combination with human polyclonal anti-rabies immune globulin. J Infect Dis 193: 796-801.
21. Prosniak M, Faber M, Hanlon CA, Rupprecht CE, Hooper DC, et al. (2003) Development of a cocktail of recombinant- expressed human rabies virus-neutralizing monoclonal antibodies for postexposure prophylaxis of rabies. J Infect Dis 188: 53-6.
22. Cai Kun, Wang Hui, Bao Shizhong, Shi Jing, Hou Xiaojun, et al. (2008) Novel human 3-domain disulfide-stabilized antibody fragment against glycoprotein of rabies virus. Microbes and Infection 10: 548-555.
23. World Health Organization. (2004) _ WHO Expert Consultation on Rabies. WHO Technical Report Series;931. Geneva, Switzerland.
24. Dietzschold B, Gore M, Marchadier D, Niu HS, Bunschoten HM, et al. (1990) Structural and immunological characterization of a linear virus-neutralizing epitope of the rabies virus glycoprotein and its possible use in a synthetic vaccine. J Virol 64: 3804-09.
25. Mebatsion T, Schnell MJ, K.K., (1995) Conzelmann, Mokola virus glycoprotein and chimeric proteins can replace rabies virus glycoprotein in the rescue of infectious defective rabies virus particles. J Virol 69: 1444-51.